Simulations Plus, Inc. (AMEX: SLP), a leading provider of ADMET absorption simulation and structure-to-property prediction software for pharmaceutical discovery and development, announced that it has received a purchase order from a very large pharmaceutical company for the renewal of a global license for a specified number of users at six sites in the U.S., Europe, and Japan.

Ron Creeley, vice president of marketing and sales of Simulations Plus, said: “This renewal is not one of the multi-year licenses that expire this fiscal year, but at a value of hundreds of thousands of dollars to one of the top three pharmaceutical companies in the world, it is a significant renewal sale. Last year, this customer’s order came in our first fiscal quarter but was timed to expire at the end of the calendar year. Now, we have received the renewal for the coming calendar year. This order covers only our GastroPlus software and extension modules, including our newly released PBPKPlus Module, for a specific number of users. Interest in our GastroPlus products continues to grow among this client’s scientists. We expect demand for additional GastroPlus licenses to grow. In addition, we anticipate licensing our new DDDPlus software at several of this customer’s research sites this calendar year and look forward to presenting our new ClassPharmer^™ product line to the client’s research chemists beginning in February.”